Investing.com -- Eli Lilly and contract manufacturer Resilience announced plans to invest $750 million to expand pharmaceutical manufacturing capacity in the United States, Resilience said Thursday.

The investment will increase production of critical medicines and create 400 new high-skilled jobs in the Cincinnati, Ohio region. Resilience's manufacturing operations in the area will now include production of Lilly's KwikPen injectable device for treating diabetes and obesity.

The multi-year manufacturing partnership between the two companies began in 2023 and has already produced more than 150 million doses of medicines for U.S. patients in vial and pre-filled syringe formats.

Edgardo Hernandez, Lilly's manufacturing head, said the partnership reflects the drugmaker's efforts to meet rising demand for its medicines.

Lilly's U.S. capital expansion commitments since 2020 total more than $55 billion. The company plans to break ground on several recently announced U.S. manufacturing sites this year.

Global drugmakers have been increasing U.S. manufacturing since last year and stockpiling inventory as the Trump administration moves to impose 100% tariffs on branded drugs unless companies cut prices or make medicines domestically.